263 related articles for article (PubMed ID: 34052583)
21. Acute iron overload and oxidative stress in brain.
Piloni NE; Fermandez V; Videla LA; Puntarulo S
Toxicology; 2013 Dec; 314(1):174-82. PubMed ID: 24120471
[TBL] [Abstract][Full Text] [Related]
22. [Curative effects and safety of deferasirox in treatment of iron overload in children with β-thalassemia major].
Gao HY; Li Q; Chen JJ; Chen GF; Li CG
Zhongguo Dang Dai Er Ke Za Zhi; 2011 Jul; 13(7):531-4. PubMed ID: 21752315
[TBL] [Abstract][Full Text] [Related]
23. Interference of deferasirox with assays for serum iron and serum unsaturated iron binding capacity during iron chelating therapy.
Ikuta K; Ito S; Tanaka H; Sasaki K; Torimoto Y; Fujiya M; Kohgo Y
Clin Chim Acta; 2011 Nov; 412(23-24):2261-6. PubMed ID: 21884685
[TBL] [Abstract][Full Text] [Related]
24. Deferasirox protects against iron-induced hepatic injury in Mongolian gerbil.
Al-Rousan RM; Rice KM; Katta A; Laurino J; Walker EM; Wu M; Triest WE; Blough ER
Transl Res; 2011 Jun; 157(6):368-77. PubMed ID: 21575921
[TBL] [Abstract][Full Text] [Related]
25. Ascorbate status modulates reticuloendothelial iron stores and response to deferasirox iron chelation in ascorbate-deficient rats.
Brewer C; Otto-Duessel M; Lykkesfeldt J; Nick H; Wood JC
Exp Hematol; 2012 Oct; 40(10):820-7. PubMed ID: 22713799
[TBL] [Abstract][Full Text] [Related]
26. Safety of deferasirox: a retrospective cohort study on the risks of gastrointestinal, liver and renal events.
Huang WF; Chou HC; Tsai YW; Hsiao FY
Pharmacoepidemiol Drug Saf; 2014 Nov; 23(11):1176-82. PubMed ID: 24946110
[TBL] [Abstract][Full Text] [Related]
27. Antioxidant Activity of Deferasirox and Its Metal Complexes in Model Systems of Oxidative Damage: Comparison with Deferiprone.
Timoshnikov VA; Kichigina LA; Selyutina OY; Polyakov NE; Kontoghiorghes GJ
Molecules; 2021 Aug; 26(16):. PubMed ID: 34443652
[TBL] [Abstract][Full Text] [Related]
28. Iron chelation by deferasirox confers protection against concanavalin A-induced liver fibrosis: A mechanistic approach.
Adel N; Mantawy EM; El-Sherbiny DA; El-Demerdash E
Toxicol Appl Pharmacol; 2019 Nov; 382():114748. PubMed ID: 31499193
[TBL] [Abstract][Full Text] [Related]
29. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
Daar S; Pathare AV
Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
[TBL] [Abstract][Full Text] [Related]
30. Deferasirox removes cardiac iron and attenuates oxidative stress in the iron-overloaded gerbil.
Al-Rousan RM; Paturi S; Laurino JP; Kakarla SK; Gutta AK; Walker EM; Blough ER
Am J Hematol; 2009 Sep; 84(9):565-70. PubMed ID: 19650117
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study.
Taher A; El-Beshlawy A; Elalfy MS; Al Zir K; Daar S; Habr D; Kriemler-Krahn U; Hmissi A; Al Jefri A
Eur J Haematol; 2009 Jun; 82(6):458-65. PubMed ID: 19187278
[TBL] [Abstract][Full Text] [Related]
32. Deferasirox for transfusion-related iron overload: a clinical review.
Lindsey WT; Olin BR
Clin Ther; 2007 Oct; 29(10):2154-66. PubMed ID: 18042472
[TBL] [Abstract][Full Text] [Related]
33. Zinc Nanoparticles Ameliorate the Reproductive Toxicity Induced by Silver Nanoparticles in Male Rats.
Shehata AM; Salem FMS; El-Saied EM; Abd El-Rahman SS; Mahmoud MY; Noshy PA
Int J Nanomedicine; 2021; 16():2555-2568. PubMed ID: 33833511
[TBL] [Abstract][Full Text] [Related]
34. Tolerability and efficacy of deferasirox in patients with transfusional iron overload: results from a German 2-year non-interventional study.
Nolte F; Nückel H; Schmidt B; Geer T; Rubanov O; Hebart H; Jarisch A; Albrecht S; Johr C; Schumann C; Hofmann WK
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1531-1538. PubMed ID: 29761371
[TBL] [Abstract][Full Text] [Related]
35. [Establishment of macrophage model of iron overload in vitro and the injury induced by oxidative stress on macrophage with iron overload].
Cao XL; Zhao MF; Li DG; Xing Y; Zhang YC; Chen J; He XY; Cui R; Meng JX; Xiao X; Mu J; Jiang YY; Wu RM
Zhonghua Yi Xue Za Zhi; 2016 Jan; 96(2):129-33. PubMed ID: 26792697
[TBL] [Abstract][Full Text] [Related]
36. Deferasirox in the treatment of iron overload during myeloproliferative neoplasms in fibrotic phase: does ferritin decrement matter?
Di Veroli A; Campagna A; De Muro M; Maurillo L; Trawinska MM; LeonettiCrescenzi S; Petriccione L; Romano A; D'Addosio A; Cenfra A; Montanaro M; Felici S; Andriani A; Carmosino I; Niscola P; Montefusco E; Breccia M; Latagliata R
Leuk Res; 2019 Jan; 76():65-69. PubMed ID: 30578958
[TBL] [Abstract][Full Text] [Related]
37. Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study.
Taher AT; Porter J; Viprakasit V; Kattamis A; Chuncharunee S; Sutcharitchan P; Siritanaratkul N; Galanello R; Karakas Z; Lawniczek T; Ros J; Zhang Y; Habr D; Cappellini MD
Blood; 2012 Aug; 120(5):970-7. PubMed ID: 22589472
[TBL] [Abstract][Full Text] [Related]
38. Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo.
Harima H; Kaino S; Takami T; Shinoda S; Matsumoto T; Fujisawa K; Yamamoto N; Yamasaki T; Sakaida I
BMC Cancer; 2016 Aug; 16(1):702. PubMed ID: 27582255
[TBL] [Abstract][Full Text] [Related]
39. Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β-thalassemia major and severe iron burden.
Voskaridou E; Komninaka V; Karavas A; Terpos E; Akianidis V; Christoulas D
Transfusion; 2014 Mar; 54(3):646-9. PubMed ID: 23834310
[TBL] [Abstract][Full Text] [Related]
40. Role of phenolics from Spondias pinnata bark in amelioration of iron overload induced hepatic damage in Swiss albino mice.
Chaudhuri D; Ghate NB; Panja S; Mandal N
BMC Pharmacol Toxicol; 2016 Jul; 17(1):34. PubMed ID: 27459849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
